ADR-201: A novel cytotoxic drug-conjugate for pancreatic cancer. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does not include a full text component.
Reply to: “Give Patients the Choice to Test for DPD Deficiency Before Fluoropyrimidine Chemotherapy,” “Large-Scale DPD Testing Should Be More Than an Option,” and “A Big Problem With a Feasible ...
The fluoropyrimidine 5-fluorouracil (5-FU) and its prodrug capecitabine, are the cornerstone of treatment of numerous types of cancer. The use of fluoropyrimidines is associated with numerous side ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback